Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The New England Journal of Medicine

Biogen Idec building

Biogen completes haemophilia business separation

Spin-out Bioverativ launched to focus exclusively on rare blood disorders

Biogen Idec building

Biogen proffers new data to support high-priced Spinraza

Trial demonstrates statistically-significant risk reduction in paediatric SMA for potential blockbuster drug

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

Biogen Idec building

FDA approves Biogen’s Spinraza for spinal muscular atrophy

Analysts predict blockbuster sales as drug is priced at $750,000 for first year of treatment

Biogen Idec building

Biogen elevates Vounatsos to top seat

US biotech’s CCO to succeed George Scangos on 6 January

Biogen Idec building

Biogen rises on more positive data for Alzheimer’s candidate

Early-stage trial throws lifeline to proponents of beleaguered amyloid hypothesis

Eli Lilly HQ

Lilly sinks as solanezumab fails again in Alzheimer’s

Amyloid-targeting drug showed no significant evidence of slow in cognitive decline

PatientsLikeMe launches ‘virtual trial’ in ALS

Partners with The Duke ALS Clinic on study of the Soy Peptide Lunasin

- PMLiVE

Biogen launches Remicade biosimilar in the UK

Flixabi provides another low-cost alternative to J&J’s biggest-selling drug

Biogen Idec building

Eisai and Biogen plan phase III trials for Alzheimer’s drug

BACE inhibitor E2609 may offer new treatment option

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links